 Spyridon Mastroyannis
Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 8 | 2023 | 484 | 0.930 |
Why?
| | Uterine Neoplasms | 3 | 2021 | 101 | 0.470 |
Why?
| | Sentinel Lymph Node | 2 | 2024 | 42 | 0.440 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2024 | 107 | 0.440 |
Why?
| | Endometrial Neoplasms | 2 | 2024 | 163 | 0.390 |
Why?
| | Genital Neoplasms, Female | 2 | 2024 | 80 | 0.390 |
Why?
| | Sarcoma, Endometrial Stromal | 2 | 2021 | 3 | 0.360 |
Why?
| | Hydatidiform Mole | 2 | 2020 | 3 | 0.340 |
Why?
| | Gestational Trophoblastic Disease | 2 | 2020 | 5 | 0.340 |
Why?
| | Lymph Node Excision | 3 | 2021 | 166 | 0.340 |
Why?
| | Granulosa Cell Tumor | 2 | 2020 | 6 | 0.340 |
Why?
| | Hysterectomy | 3 | 2021 | 118 | 0.250 |
Why?
| | Enoxaparin | 1 | 2024 | 59 | 0.220 |
Why?
| | Pyridones | 1 | 2024 | 159 | 0.200 |
Why?
| | Leiomyosarcoma | 1 | 2021 | 27 | 0.180 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 12 | 0.180 |
Why?
| | Pyrazoles | 1 | 2024 | 403 | 0.180 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.170 |
Why?
| | Vacuum Curettage | 1 | 2020 | 5 | 0.170 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 17 | 0.170 |
Why?
| | Organ Sparing Treatments | 1 | 2020 | 32 | 0.170 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 5 | 0.160 |
Why?
| | CA-125 Antigen | 1 | 2019 | 15 | 0.160 |
Why?
| | Neoplasm Staging | 5 | 2022 | 1286 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 66 | 0.160 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.150 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 108 | 0.150 |
Why?
| | Vaccines | 1 | 2023 | 403 | 0.150 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2018 | 35 | 0.150 |
Why?
| | Leuprolide | 1 | 2017 | 19 | 0.140 |
Why?
| | Prognosis | 5 | 2024 | 3793 | 0.140 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 36 | 0.140 |
Why?
| | Female | 22 | 2024 | 68274 | 0.140 |
Why?
| | Middle Aged | 13 | 2024 | 31024 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2018 | 459 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 626 | 0.120 |
Why?
| | Succinate Dehydrogenase | 1 | 2015 | 44 | 0.120 |
Why?
| | Estrogens | 1 | 2017 | 348 | 0.120 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2014 | 2 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 4927 | 0.120 |
Why?
| | Pheochromocytoma | 1 | 2015 | 57 | 0.110 |
Why?
| | Cushing Syndrome | 1 | 2014 | 10 | 0.110 |
Why?
| | Age Determination by Skeleton | 1 | 2014 | 18 | 0.110 |
Why?
| | Paraganglioma | 1 | 2015 | 49 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2024 | 14562 | 0.110 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2015 | 84 | 0.110 |
Why?
| | Bone Development | 1 | 2014 | 48 | 0.110 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 135 | 0.110 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2014 | 132 | 0.110 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 184 | 0.100 |
Why?
| | Adenoma | 1 | 2015 | 210 | 0.100 |
Why?
| | Glucose Intolerance | 1 | 2014 | 142 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2024 | 2497 | 0.100 |
Why?
| | Humans | 23 | 2024 | 129078 | 0.100 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 134 | 0.100 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2012 | 10 | 0.100 |
Why?
| | Fatty Liver | 1 | 2014 | 230 | 0.100 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 53 | 0.090 |
Why?
| | Aged | 8 | 2024 | 22068 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 312 | 0.090 |
Why?
| | Obesity | 2 | 2014 | 2847 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2014 | 588 | 0.090 |
Why?
| | Chorionic Gonadotropin | 2 | 2020 | 80 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2022 | 380 | 0.080 |
Why?
| | SEER Program | 2 | 2020 | 208 | 0.080 |
Why?
| | Registries | 3 | 2022 | 1916 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 642 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 952 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2020 | 278 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1221 | 0.070 |
Why?
| | Bone Density | 1 | 2012 | 470 | 0.070 |
Why?
| | Adult | 8 | 2024 | 35423 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2116 | 0.070 |
Why?
| | United States | 5 | 2022 | 13992 | 0.070 |
Why?
| | Survival Rate | 2 | 2021 | 1886 | 0.060 |
Why?
| | Liver | 1 | 2014 | 1835 | 0.060 |
Why?
| | Young Adult | 5 | 2020 | 12310 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7063 | 0.060 |
Why?
| | Adolescent | 6 | 2020 | 20241 | 0.060 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2024 | 54 | 0.060 |
Why?
| | Adoptive Transfer | 1 | 2023 | 217 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2635 | 0.050 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 171 | 0.050 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 271 | 0.040 |
Why?
| | Dysgerminoma | 1 | 2020 | 6 | 0.040 |
Why?
| | Endodermal Sinus Tumor | 1 | 2020 | 8 | 0.040 |
Why?
| | Child | 5 | 2020 | 20860 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 61 | 0.040 |
Why?
| | Anticoagulants | 1 | 2024 | 622 | 0.040 |
Why?
| | Child, Preschool | 3 | 2020 | 10462 | 0.040 |
Why?
| | Fertility Preservation | 1 | 2020 | 54 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5400 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 861 | 0.040 |
Why?
| | Receptors, LH | 1 | 2017 | 9 | 0.040 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2017 | 17 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2015 | 2774 | 0.040 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2017 | 46 | 0.040 |
Why?
| | Pregnancy | 2 | 2020 | 6256 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2017 | 142 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1283 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 9804 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1913 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1351 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 778 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1289 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 140 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2157 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 391 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1697 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 2080 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2014 | 240 | 0.030 |
Why?
| | Male | 5 | 2020 | 63248 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 255 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3290 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2530 | 0.020 |
Why?
| | Mice | 2 | 2015 | 16583 | 0.020 |
Why?
| | Infant | 1 | 2020 | 8997 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5282 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10256 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6579 | 0.010 |
Why?
| | Animals | 2 | 2015 | 34708 | 0.010 |
Why?
|
|
Mastroyannis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|